

AI Research Priorities Survey Invitation

Luis Pinheiro and Amanda Langston, EMA

Survey context

- HMA/EMA are committed to ensuring AI applications in medicines development and evaluation are safe, effective, and aligned with regulations and best practices.
- Diverse research needs and priorities for AI use were identified in a 2024 HMA/EMA workshop.
- Building on this broad initial feedback, EMA has built a survey for structured stakeholder feedback.
- Stakeholders include the EMRN, industry, SMEs, patients, consumers, academics, and healthcare professionals.



Survey objectives

1. To accelerate the understanding of stakeholder perspectives on key opportunities and challenges related to the use of AI in medicine development.



2. To use these insights to identify areas of further research that can help reduce uncertainty and facilitate the safe and effective use of AI.



3. To publish these research areas to inform researchers at large of HMA and EMA regulatory priorities.

Why participate?

**Inform regulatory
research priorities for AI
in medicines.**

**Support transparent and
inclusive AI research to
address real-world
needs.**

**Contribute to a safer,
more effective AI
ecosystem in medicines.**

Survey opens: 29 September

Survey closes: 17 October

Link to survey: <https://ec.europa.eu/eusurvey/runner/AI-Priorities-Stakeholder-Survey>



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

Amanda.Langston@ext.ema.europa.eu

Follow us



Upcoming meetings

ACT EU multi-stakeholder platform annual meeting

22 October 2024 (09:30 - 17:00)

[EMA event page](#) and [Draft agenda for webinar on shortages](#)

Public webinar on shortages: putting patients first

4 November 2025 (14:00 - 16:00)

[EMA event page](#) and [Draft agenda for webinar on shortages](#)

HMA-EMA annual multistakeholder data forum

9 December 2025 (09:30 - 17:30)

[EMA event page](#)

Multistakeholder workshop on Patient Registries for Alzheimer's Disease

15 December 2025

[EMA event page](#)

LinkedIn Live interview



Smarter trials, stronger Europe. New targets for clinical research

LinkedIn Live interview with:

Ana Zanoletty, Head of Clinical Trials Transformation, EMA

Corinna Hartung, Policy Officer, DG SANTE, European Commission

Marianne Lunzer, Chair HMA Clinical Trials Coordination Group, AGES

Wednesday, 24 September 2025

14:00 (CEST)



Recording will be available
on LinkedIn

Follow EMA on LinkedIn for
more live events